Akanda

Akanda Net Margin

The Net Profit Margin of Akanda (AKAN) as of Oct 25, 2026 is -17,690.19 %. In the previous year, Net Profit Margin was -489.57 % — a change of 3,513.44% (lower).

Net Margin

-17,690.19 %

YoY

3,513.44%

Last updated:

Net Profit Margin of Akanda is 2025 -17,690.19 % . Net Profit Margin of Akanda was 2024 -489.57 % . It decreases by 3,513.44% lower compared to the previous year.

For Akanda, the net margin of -17,690.2% is up versus -19,625.9% a few years ago.

The Akanda Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2020
-111,569.88 USD
Jan 1, 2021
-19,625.88 USD
Jan 1, 2022
-445.00 USD
Jan 1, 2023
-1,494.18 USD
Jan 1, 2024
-489.57 USD
Jan 1, 2025
-17,690.19 USD
The Akanda Net Margin history
YEARNet MarginYoY
-17,690.19 %+3,513.44%
-489.57 %-67.24%
-1,494.18 %+235.77%
-445.00 %-97.73%
-19,625.88 %-82.41%
-111,569.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Net Profit Margin of Akanda is -17,690.19 % in 2025.

Net Profit Margin of Akanda changed from -489.57 % to -17,690.19 %, representing a 3,513.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Akanda since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Akanda

All Key Metrics — Akanda